Chengdu Olymvax Biopharmaceuticals (SHSE:688319) ROCE % : 8.13% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chengdu Olymvax Biopharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chengdu Olymvax Biopharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was 8.13%.

Chengdu Olymvax Biopharmaceuticals ROCE % Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Olymvax Biopharmaceuticals ROCE % Chart

Chengdu Olymvax Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

9.77

17.05

5.25

2.18

3.12

Chengdu Olymvax Biopharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-4.16	-8.49	0.09	12.01	8.13

Chengdu Olymvax Biopharmaceuticals ROCE % Calculation

Chengdu Olymvax Biopharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	36.588	/	( ( (1612.606 - 476.219)	+	(1807.043 - 595.594) )	/ 2 )
	=	36.588	/	( (1136.387	+	1211.449)	/ 2 )
	=	36.588	/	1173.918
	=	3.12 %

Chengdu Olymvax Biopharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	99.028	/	( ( (1707.578 - 483.828)	+	(1807.043 - 595.594) )	/ 2 )
	=	99.028	/	( ( 1223.75	+	1211.449 )	/ 2 )
	=	99.028	/	1217.5995
	=	8.13 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chengdu Olymvax Biopharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Chengdu Olymvax Biopharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chengdu Olymvax Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731

Website

http://www.olymvax.com

Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.

Executives

Chen Dao Yuan	Core technical personnel
Li Hong Guang	Core technical personnel
Fan Shao Wen	Directors, senior managers
Ma Heng Jun	senior management
Wu Wei	senior management
Fan Fan	Director
Chen Ai Min	Director
Tan Yong	senior management
Lu Lu	Director
Yu Yun Hui	Director
Zhang Li Ying	Core technical personnel
Chen Ke Ping	Core technical personnel
Wu Qiang	Core technical personnel
Yang Feng	Core technical personnel

Chengdu Olymvax Biopharmaceuticals Headlines

No Headlines